Meta-analysis: Methodology
|
|
- Mervin Barrett
- 5 years ago
- Views:
Transcription
1 Meta-analysis: Methodology Example: Assessment of cardiovascular safety profile of new generation BCR-ABL TKIs in patients with CML Haguet Hélène 04/03/2016
2 Meta-analysis = statistical combination of results from two or more separate studies to answer a common question Compute effect size + variance for each study Assign weights based on study variance Compute the weighted mean Assign weight depending of the study precision Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 2
3 Design the protocol Rationale potential interest PRISMA protocols Objectives: define the question: PICO Participants (diseases, conditions) Interventions (treated arm) Comparators (control arm) Outcomes of interest Eligibility criteria: PICO + study design Search strategy Data collection Statistical analysis (model) Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results Shamseer L, et al. Bmj. 2015;349:g
4 Random or fixed-effect model? Fixed-effect model Estimates a single effect that is assumed to be common to every study Random-effects model Allow that the true effect size may vary from study to study Observed variance = within-studies + between-studies variance both used in weights assignment Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 4
5 Random or fixed-effect model? Fixed-effect model Random-effects model Borenstein M, et al. 2010;1(2): Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 5
6 Databases Bibliographic databases Search strategy E.g. PubMed, Scopus, Cochrane Library, EMBASE Abstracts from international congresses Clinical trial registers E.g. WHO international clinical trial register, EudraCT Keywords and Boolean operators Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 6
7 Search strategy Example #1: ponatinib [Title] (69) #2: AP24534 [Title] (8) #3: ((#1) OR #2) (71) #4: (#3) and "randomized controlled trial" (1) #5: (#3) and "randomized trial" (0) #6: (#3) and "randomized clinical trial" (0) #7: (#3) and "randomised controlled trial" (0) #8: (#3) and "randomised trial" (0) #9: (#3) and "randomised clinical trial" (0) #10: (((((#4) OR #5) OR #6) OR #7) OR #8) OR #9 (1) Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 7
8 Study selection Removal of duplicates In 2 stages Screening of abstracts and titles independently by 2 reviewers (+ discussion with 3 rd reviewers) Selection of included studies based on the entirety of the paper Process described in flow diagram PRISMA statement Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 8
9 PRISMA flow chart Moher D, et al. Bmj. 2009;339:b2535. Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 9
10 Quality assessment Use quality scoring system By 2 reviewers independently Exclude low quality studies E.g JADAD score, Chalmers scale Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 10
11 Data collection Extracted by 2 independent reviewers Standardized data extraction form E.g. study characteristics, study design, population, outcomes Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 11
12 Data collection Selection of data by the 2 reviewers Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 12
13 Statistical analysis Direction and size of the effect? Effect size measure + 95%CI Is the effect consistent across studies? Heterogeneity assessment What is the strength of evidence for the effect? Quality assessment Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 13
14 Effect size measures = summarises the observed intervention effect Depend of the type of data Means (e.g. improvement of blood pressure) Binary data (e.g. survival) Correlational data Binary data Risk ratio Odds ratio (often the best choice) Risk difference Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 14
15 Statistical analysis Comprehensive Meta-Analysis software version Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 15
16 Heterogeneity assessment Cochran s Q statistics Reported with p value Low power to detect heterogeneity Common use of 0.10 as cut-off value for significance I 2 statistic I 2 : % of observed total variation across studies that is due to real heterogeneity rather than chance <25%: low heterogeneity 25-50%: moderate heterogeneity 50-75%: high heterogeneity Less dependent of the number of studies Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 16
17 Heterogeneity assessment No heterogeneity: similar to fixed-effect model In case of heterogeneity: Explore the causes: Subgroup analysis (!! False negative and positive) E.g. Treatments, population characteristics Meta-regression Check data and effect size measure Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 17
18 Assessing risk of bias Publication bias Funnel plots Assessment of the funnel plot asymmetry Egger s linear regression test Begg and Mazumbar rank correlation test Fail-safe number = how many new studies averaging a null result are required to bring the overall treatment effect to nonsignificant Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 18
19 One-way sensitivity analysis Aim: explore the robustness of the findings Remove one single study at a time Vascular occlusive events Study name Treatment Statistics with study removed Peto odds ratio (95% Lower Upper CI) with study removed Point limit limit p-value NCT EPIC Ponatinib 3,410 2,317 5,020 0,000 NCT BELA Bosutinib 3,443 2,382 4,977 0,000 NCT ENESTnd Nilotinib 3,518 2,140 5,785 0,000 NCT ENESTcmr Nilotinib 3,335 2,293 4,852 0,000 NCT ENESTchina Nilotinib 3,395 2,360 4,885 0,000 NCT LASOR Nilotinib 3,303 2,281 4,782 0,000 NCT NordCML006 Dasatinib 3,392 2,358 4,881 0,000 NCT Dasatinib 3,395 2,360 4,884 0,000 NCT DASISION Dasatinib 3,321 2,278 4,840 0,000 NCT START-R Dasatinib 3,404 2,363 4,903 0,000 NCT Dasatinib 3,524 2,449 5,070 0,000 NCT SPIRIT2 Dasatinib 3,645 2,465 5,390 0,000 3,418 2,379 4,909 0,000 0,01 0, Imatinib New generation TKI Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results Douxfils J, et al. JAMA Oncol
20 Forest plot Douxfils J, et al. Journal of the American Heart Association. 2014;3(3):e Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 20
21 Guidelines: PRISMA checklist Moher D, et al. Bmj. 2009;339:b
22 Guidelines: PRISMA checklist Moher D, et al. Bmj. 2009;339:b
23 Criticisms 1 number cannot summarize a research field Assessment of heterogeneity and dispersion between studies Publication bias overestimation of the true effect size Assessed by funnel plot + asymmetry tests Mixing apples and oranges If heterogeneity between studies, it should be investigated Be clear and transparent 23
24 Resources Borenstein M, et al. Introduction to Meta-Analysis Cooper H, et al. The Handbook of Research Synthesis and Meta-Analysis, 2nd Edition Higgins J, et al, Cochrane Handbook for Systematic Reviews of Interventions 24
25
26 Vascular occlusive events Ponatinib: arterial and venous occlusive events identified 1 Temporal suspension of ponatinib marketing (FDA decision) Early abortion of the phase III clinical trial (EPIC trial) Risk minimization measures 2 1 Giles, F. J. et al. Leukemia 27(6): EMA. European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots 1
27 Vascular occlusive events Dasatinib: no vascular occlusive events 3 Bosutinib: no vascular occlusive events 4 Nilotinib: serious cases of PAOD 5,6 Cardiac and arterial occlusive events included in labeling information 3 Food and Drug Administration. Label information SPRYCEL. 4 Food and Drug Administration. Label information BOSULIF. 5 Food and Drug Administration. "Label information - TASIGNA." 6 Quintas-Cardama A., et al. Clin Lymphoma Myeloma Leuk 12(5):
28 Rationales TKIs may alter other tyrosine kinases class effect? 7 2nd generation TKIs have demonstrated higher efficacy on surrogate outcomes in the treatment of CML 7 Giles, F. J. et al. (2013). Leukemia 27(6):
29 Question Risk of CV occlusive events associated to new generation BCR-ABL TKIs in CML compared with imatinib? Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results 4
30 Systematic review and Metaanalysis Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results Protocol: online registration: PROSPERO 2014: CDR Literature search: Scientific articles: Pubmed, scopus and Cochrane library Congress abstracts: ASH, ASCO, ESMO Clinical trial register: Study selection: Randomized clinical trials Comparing new generation TKIs vs imatinib Patients with CML 5
31 Systematic review and Metaanalysis Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results Data collection: Vascular occlusive events (+ OS and MMR) Arterial occlusive events, venous occlusive events Study characteristics, population characteristics, JADAD scale Statistical analysis: Random-effects model Exception: fixed-effect model for venous occlusive events Effect size measure: Odds ratio using Peto method 6
32 Peto odds ratio Odds Ratio Peto Odds Ratio OR = AD BC Brockhaus AC, et al. Statistics in medicine. 2014;33(28):
33 Systematic review and Metaanalysis Problem formulation Literature search Study selection Data collection Statistical analysis Reporting the results Statistical analysis: Stratification By treatment Heterogeneity Q statistic I 2 value Publication bias: funnel plots Robustness: 1-way sensitivity analysis 8
34 Vascular occlusive events 8 Vascular occlusive events atment Group by Comparison Study name Statistics for each study Peto odds ratio and 95% CI Peto Lower Upper Relative odds ratio limit limit p-value weight sutinib Bosutinib NCT BELA 2,768 0,388 19,769 0, ,00 Bosutinib 2,768 0,388 19,769 0,310 atinib Dasatinib NCT NordCML006 8,092 0, ,341 0,296 3,30 atinib Dasatinib NCT ,389 0, ,385 0,317 3,31 atinib Dasatinib NCT DASISION 4,855 1,301 18,120 0,019 29,30 atinib Dasatinib NCT START-R 4,460 0,230 86,505 0,323 5,78 atinib Dasatinib NCT ,085 0,002 4,614 0,227 3,19 atinib Dasatinib NCT SPIRIT2 2,317 0,887 6,052 0,086 55,12 Dasatinib 2,913 1,428 5,942 0,003 otinib Nilotinib NCT ENESTnd 3,307 1,949 5,611 0,000 80,15 otinib Nilotinib NCT ENESTcmr 4,826 1,178 19,777 0,029 11,26 otinib Nilotinib NCT ENESTchina 7,334 0, ,606 0,319 1,46 otinib Nilotinib NCT LASOR 7,475 1,270 43,982 0,026 7,13 Nilotinib 3,700 2,305 5,940 0,000 atinib Ponatinib NCT EPIC 3,470 1,231 9,779 0, ,00 Ponatinib 3,470 1,231 9,779 0,019 Overall 3,418 2,379 4,909 0,000 0,01 0, Imatinib New generation TKI 8 Douxfils J, et al. JAMA Oncol
35 Vascular occlusive events 8 Vascular occlusive events atment Group by Comparison Study name Statistics for each study Peto odds ratio and 95% CI Peto Lower Upper Relative odds ratio limit limit p-value weight sutinib Bosutinib NCT BELA 2,768 0,388 19,769 0, ,00 Bosutinib 2,768 0,388 19,769 0,310 atinib Dasatinib NCT NordCML006 8,092 0, ,341 0,296 3,30 atinib Dasatinib NCT ,389 0, ,385 0,317 3,31 Bosutinib: 3 events/248 pts atinib Dasatinib NCT DASISION 4,855 1,301 18,120 0,019 29,30 atinib Dasatinib NCT START-R 4,460 0,230 86,505 0,323 Imatinib: 1 event/251 pts 5,78 atinib Dasatinib NCT ,085 0,002 4,614 0,227 3,19 atinib Dasatinib NCT SPIRIT2 2,317 0,887 6,052 0,086 55,12 Dasatinib 2,913 1,428 5,942 0,003 otinib Nilotinib NCT ENESTnd 3,307 1,949 5,611 0,000 80,15 otinib Nilotinib NCT ENESTcmr 4,826 1,178 19,777 0,029 11,26 otinib Nilotinib NCT ENESTchina 7,334 0, ,606 0,319 1,46 otinib Nilotinib NCT LASOR 7,475 1,270 43,982 0,026 7,13 Nilotinib 3,700 2,305 5,940 0,000 atinib Ponatinib NCT EPIC 3,470 1,231 9,779 0, ,00 Ponatinib 3,470 1,231 9,779 0,019 Overall 3,418 2,379 4,909 0,000 0,01 0, Imatinib New generation TKI 8 Douxfils J, et al. JAMA Oncol
36 Vascular occlusive events 8 Vascular occlusive events atment Group by Comparison Study name Statistics for each study Peto odds ratio and 95% CI Peto Lower Upper Relative odds ratio limit limit p-value weight sutinib Bosutinib NCT BELA 2,768 0,388 19,769 0, ,00 Bosutinib 2,768 0,388 19,769 0,310 atinib Dasatinib NCT NordCML006 8,092 0, ,341 0,296 3,30 atinib Dasatinib NCT ,389 0, ,385 0,317 3,31 atinib Dasatinib NCT DASISION 4,855 1,301 18,120 0,019 29,30 atinib Dasatinib NCT START-R 4,460 0,230 86,505 0,323 5,78 atinib Dasatinib NCT ,085 0,002 4,614 0,227 3,19 atinib Dasatinib NCT SPIRIT2 2,317 0,887 6,052 0,086 55,12 Dasatinib (overall) 2,913 1,428 5,942 0,003 otinib Nilotinib NCT ENESTnd 3,307 1,949 5,611 0,000 80,15 otinib Nilotinib NCT ENESTcmr 4,826 1,178 19,777 0,029 11,26 otinib Nilotinib NCT ENESTchina 7,334 0, ,606 0,319 1,46 otinib Nilotinib NCT LASOR 7,475 1,270 43,982 0,026 7,13 Nilotinib (overall) 3,700 2,305 5,940 0,000 atinib Ponatinib NCT EPIC 3,470 1,231 9,779 0, ,00 Ponatinib (overall) 3,470 1,231 9,779 0,019 Overall 3,418 2,379 4,909 0,000 0,01 0, Imatinib New generation TKI 8 Douxfils J, et al. JAMA Oncol
37 Limitations Lack of individual data Time to event Number of deaths due to VOE Lack of homogeneity in evaluation criteria (VOE) between studies 8,9 8 Yang EH, et al. Future Oncol. 11(14): Groarke JD, et al. The New England journal of medicine. 369(19):
38 Strengths Consistent with the signal Robustness confirmed by the sensitivity analysis No heterogeneity between studies No evidence of publication bias Published & unpublished studies included 14
39 Standard Error Funnel plot Funnel Plot of Standard Error by Log Peto odds ratio Log Peto odds ratio 15
40 6th NTHC symposium 18
41 Acknowledgments Douxfils Jonathan Mullier François Chatelain Christian Graux Carlos Dogné Jean-Michel 42
42 Thank you for your attention!
43 PRISMA protocol checklist Shamseer L, et al. Bmj. 2015;349:g7647.
44 PRISMA protocol checklist Shamseer L, et al. Bmj. 2015;349:g7647.
45 FEM vs REM Both: weights depend of the precision of the estimation (= of the overall study error variance) Difference REM vs FEM: definition of this variance Fixed-effect model Only 1 source of variation: the estimation error ε i = difference between common true mean and observed mean Within-study variance depends of: - The variance of individual observation - The size of the sample Random-effects model 2 sources of variation - The estimation error within study ε i - The estimation error between study ξ i Overall study error variance: combination of the variance of these 2 parameters Borenstein M, et al. 2010;1(2):
46 FEM vs REM Fixed-effect model Random-effect model ε 1 ε 1 ξ 1 Adapted from Borenstein M, et al. 2010;1(2): Adapted from Borenstein M, et al. 2010;1(2): Circle: true mean Square: observed mean (differs from the true mean because of estimation error)
47 Raw mean difference Effect size: means Only if studies used the same scale Standardized mean difference In case of different evaluation of the outcome (the scale of measurement differed) Division of the mean difference in each study by study s standard deviation Response ratios When the measure is unlikely to be 0, but has a natural 0 point (e.g. length)
48 Odds ratio vs risk ratio Divergence large when the outcome is common Avoid quantitative statements about OR Holcomb WL, Jr., et al. Obstetrics and gynecology. 2001;98(4):685-8.
49 Meta-analysis of observational studies Controversial: potential biases Diversity of study designs and populations Publication bias (could have particular impact) Recommendations: Use broad inclusion criteria Perform analysis relating suspected source of bias and variability Investigate heterogeneity Stroup DF, et al. JAMA. 2000;283(15):
50 Meta-analysis of single-arm clinical trials Controversial: lack of control: effect of site-specific variables Interrupted-time series (ITS) study For studies with multiple time-points before and after an intervention (at least 3 data points before and 3 after the intervention) Repeated measures study: if the measures are repeated in the same individuals Effective Practice and Organisation of Care (EPOC) Available at: 51
51 Effective Practice and Organisation of Care (EPOC) Available at: 52
Supplementary Online Content
Supplementary Online Content Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné J-M. Use of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and metaanalysis
More informationImatinib & Ponatinib. Two ends of the spectrum in 2016s reality
Imatinib & Ponatinib Two ends of the spectrum in 2016s reality CML 2016 Benefits & risks Steve O Brien CML Horizons, May 2016 Disclosures Research funding, participation in company trial, speaker, consultant,
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationHow to Conduct a Meta-Analysis
How to Conduct a Meta-Analysis Faculty Development and Diversity Seminar ludovic@bu.edu Dec 11th, 2017 Periodontal disease treatment and preterm birth We conducted a metaanalysis of randomized controlled
More informationMeta Analysis. David R Urbach MD MSc Outcomes Research Course December 4, 2014
Meta Analysis David R Urbach MD MSc Outcomes Research Course December 4, 2014 Overview Definitions Identifying studies Appraising studies Quantitative synthesis Presentation of results Examining heterogeneity
More informationMeta-Analysis. Zifei Liu. Biological and Agricultural Engineering
Meta-Analysis Zifei Liu What is a meta-analysis; why perform a metaanalysis? How a meta-analysis work some basic concepts and principles Steps of Meta-analysis Cautions on meta-analysis 2 What is Meta-analysis
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More informationThe QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews
The QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews David Moher 1, Alessandro Liberati 2, Douglas G Altman 3, Jennifer Tetzlaff 1 for the QUOROM Group
More informationIntroduction to systematic reviews/metaanalysis
Introduction to systematic reviews/metaanalysis Hania Szajewska The Medical University of Warsaw Department of Paediatrics hania@ipgate.pl Do I needknowledgeon systematicreviews? Bastian H, Glasziou P,
More informationDabigatran etexilate, the prodrug of dabigatran, an oral
Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials Jonathan
More informationMeta-analysis: Basic concepts and analysis
Meta-analysis: Basic concepts and analysis Matthias Egger Institute of Social & Preventive Medicine (ISPM) University of Bern Switzerland www.ispm.ch Outline Rationale Definitions Steps The forest plot
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationCML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
More informationWorkshop: Cochrane Rehabilitation 05th May Trusted evidence. Informed decisions. Better health.
Workshop: Cochrane Rehabilitation 05th May 2018 Trusted evidence. Informed decisions. Better health. Disclosure I have no conflicts of interest with anything in this presentation How to read a systematic
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationResearch Synthesis and meta-analysis: themes. Graham A. Colditz, MD, DrPH Method Tuuli, MD, MPH
Research Synthesis and meta-analysis: themes Graham A. Colditz, MD, DrPH Method Tuuli, MD, MPH Today Course format Goals, competencies Overview of themes for the class SRMA M19-551 Course Format Lectures»
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationThe Meta on Meta-Analysis. Presented by Endia J. Lindo, Ph.D. University of North Texas
The Meta on Meta-Analysis Presented by Endia J. Lindo, Ph.D. University of North Texas Meta-Analysis What is it? Why use it? How to do it? Challenges and benefits? Current trends? What is meta-analysis?
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More information1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with
1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with both Nilotinib and Dasatinib. Nilotinib for the cardio
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationSYSTEMATIC REVIEW: AN APPROACH FOR TRANSPARENT RESEARCH SYNTHESIS
SYSTEMATIC REVIEW: AN APPROACH FOR TRANSPARENT RESEARCH SYNTHESIS A Case Study By Anil Khedkar, India (Masters in Pharmaceutical Science, PhD in Clinical Research Student of Texila American University)
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationFixed Effect Combining
Meta-Analysis Workshop (part 2) Michael LaValley December 12 th 2014 Villanova University Fixed Effect Combining Each study i provides an effect size estimate d i of the population value For the inverse
More informationIclusig. Iclusig (ponatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.30 Subject: Iclusig Page: 1of 6 Last Review Date: June 22, 2018 Iclusig Description Iclusig (ponatinib)
More informationPrinciples of meta-analysis
Principles of meta-analysis 1 The popularity of meta-analyses Search on 22 October 2015 10000 9000 8156 8875 8000 7000 6554 6000 5000 4852 4000 3000 2000 1000 0 1 1 1 272 334 371 323 386 429 482 596 639
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with first
More informationResults. NeuRA Worldwide incidence April 2016
Introduction The incidence of schizophrenia refers to how many new cases there are per population in a specified time period. It is different from prevalence, which refers to how many existing cases there
More informationPonatinib Withdrawal Update
Hello. This is Dr. Stuart Goldberg from the Leukemia Division at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey. I am speaking on behalf of ManagingCML.com
More informationDose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus
Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus Hadera I Oct 2018 Front-line Randomized Trials in CML-CP Trial Drugs References IRIS IM 400 vs IFN/AraC TOPS IM
More informationModels for potentially biased evidence in meta-analysis using empirically based priors
Models for potentially biased evidence in meta-analysis using empirically based priors Nicky Welton Thanks to: Tony Ades, John Carlin, Doug Altman, Jonathan Sterne, Ross Harris RSS Avon Local Group Meeting,
More informationPerformance of the Trim and Fill Method in Adjusting for the Publication Bias in Meta-Analysis of Continuous Data
American Journal of Applied Sciences 9 (9): 1512-1517, 2012 ISSN 1546-9239 2012 Science Publication Performance of the Trim and Fill Method in Adjusting for the Publication Bias in Meta-Analysis of Continuous
More informationIclusig. Iclusig (ponatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.30 Section: Prescription Drugs Effective Date: April 1, 2017 Subject: Iclusig Page: 1of 5 Last Review
More informationResults. NeuRA Hypnosis June 2016
Introduction may be experienced as an altered state of consciousness or as a state of relaxation. There is no agreed framework for administering hypnosis, but the procedure often involves induction (such
More informationApplying Evidence-Based Practice with Meta-Analysis
Applying Evidence-Based Practice with Meta-Analysis Mike W.-L. Cheung, PhD 1 1 March 2018 1 Department of Psychology, National University of Singapore (NUS) 1 A little bit background about me (1) PhD:
More informationRobert M. Jacobson, M.D. Department of Pediatric and Adolescent Medicine Mayo Clinic, Rochester, Minnesota
How to Conduct a Systematic Review: A Workshop 24 th Annual Primary Care Research Methods & Statistics Conference, San Antonio, Texas Saturday, December 3, 2011 Robert M. Jacobson, M.D. Department of Pediatric
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More information18/11/2013. An Introduction to Meta-analysis. In this session: What is meta-analysis? Some Background Clinical Trials. What questions are addressed?
In this session: What is meta-analysis? An Introduction to Meta-analysis Geoff Der Unit Statistician MRC/CSO Social and Public Health Sciences Unit, University of Glasgow When is it appropriate to use?
More informationCritical appraisal: Systematic Review & Meta-analysis
Critical appraisal: Systematic Review & Meta-analysis Atiporn Ingsathit MD.PhD. Section for Clinical Epidemiology and biostatistics Faculty of Medicine Ramathibodi Hospital Mahidol University What is a
More informationBackground: Traditional rehabilitation after total joint replacement aims to improve the muscle strength of lower limbs,
REVIEWING THE EFFECTIVENESS OF BALANCE TRAINING BEFORE AND AFTER TOTAL KNEE AND TOTAL HIP REPLACEMENT: PROTOCOL FOR A SYSTEMATIC RE- VIEW AND META-ANALYSIS Background: Traditional rehabilitation after
More informationChoice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias
Technical appendix Choice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias Choice of axis in funnel plots Funnel plots were first used in educational research and psychology,
More informationLearning from Systematic Review and Meta analysis
Learning from Systematic Review and Meta analysis Efficacy and Safety of Antiscabietic Agents: A Systematic Review and Network Meta analysis of Randomized Controlled Trials KUNLAWAT THADANIPON, MD 4 TH
More informationDisclosures. An Introduction to Meta Analysis. Biography, SL Norris 2/20/2012
An Introduction to Meta Analysis Susan L. Norris, MD, MPH, MS Associate Professor Oregon Health & Science University Portland, OR norriss@ohsu.edu Biography, SL Norris MD, MS, University of Alberta MPH,
More informationResults. NeuRA Treatments for internalised stigma December 2017
Introduction Internalised stigma occurs within an individual, such that a person s attitude may reinforce a negative self-perception of mental disorders, resulting in reduced sense of selfworth, anticipation
More informationAcupuncture combined with herbal medicine versus herbal medicine alone for plaque psoriasis: a systematic review protocol
Study Protocol Page 1 of 6 Acupuncture combined with herbal medicine versus herbal medicine alone for plaque psoriasis: a systematic review protocol Shiju Xiao 1,2, Bo Li 3, Shuo Feng 3, Cunzhi Liu 4,
More informationNeuRA Sleep disturbance April 2016
Introduction People with schizophrenia may show disturbances in the amount, or the quality of sleep they generally receive. Typically sleep follows a characteristic pattern of four stages, where stage
More informationSummary 1. Comparative effectiveness of ponatinib
Cost-effectiveness of ponatinib (Iclusig ) as indicated for adult patients with: (i) CP-, AP-, or BP- chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to
More informationProblem solving therapy
Introduction People with severe mental illnesses such as schizophrenia may show impairments in problem-solving ability. Remediation interventions such as problem solving skills training can help people
More informationMeta-analysis of diagnostic research. Karen R Steingart, MD, MPH Chennai, 15 December Overview
Meta-analysis of diagnostic research Karen R Steingart, MD, MPH karenst@uw.edu Chennai, 15 December 2010 Overview Describe key steps in a systematic review/ meta-analysis of diagnostic test accuracy studies
More informationIclusig. Iclusig (ponatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.30 Subject: Iclusig Page: 1of 5 Last Review Date: June 24, 2016 Iclusig Description Iclusig (ponatinib)
More informationVascular safety profile of new generation BCR-ABL tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia
45 Vascular safety profile of new generation BCR-ABL tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia H. Haguet, MBS 1,2, J. Douxfils, PharmD, PhD1, F. Mullier, PharmD, PhD2, C.
More informationSystematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)
Systematic Review & Meta-analysisanalysis Ammarin Thakkinstian, Ph.D. Section for Clinical Epidemiology and Biostatistics Faculty of Medicine, Ramathibodi Hospital Tel: 02-201-1269, 02-201-1762 Fax: 02-2011284
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationSchool of Dentistry. What is a systematic review?
School of Dentistry What is a systematic review? Screen Shot 2012-12-12 at 09.38.42 Where do I find the best evidence? The Literature Information overload 2 million articles published a year 20,000 biomedical
More informationExecutive summary Overview
Executive summary Overview In this appraisal, we have demonstrated that dasatinib is clinically more effective, as well as more cost effective, than imatinib, the current standard of care. In the pivotal
More informationTypes of Data. Systematic Reviews: Data Synthesis Professor Jodie Dodd 4/12/2014. Acknowledgements: Emily Bain Australasian Cochrane Centre
Early Nutrition Workshop, December 2014 Systematic Reviews: Data Synthesis Professor Jodie Dodd 1 Types of Data Acknowledgements: Emily Bain Australasian Cochrane Centre 2 1 What are dichotomous outcomes?
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationC2 Training: August 2010
C2 Training: August 2010 Introduction to meta-analysis The Campbell Collaboration www.campbellcollaboration.org Pooled effect sizes Average across studies Calculated using inverse variance weights Studies
More informationEvaluating the results of a Systematic Review/Meta- Analysis
Open Access Publication Evaluating the results of a Systematic Review/Meta- Analysis by Michael Turlik, DPM 1 The Foot and Ankle Online Journal 2 (7): 5 This is the second of two articles discussing the
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationMeta-analyses: analyses:
Meta-analyses: analyses: how do they help, and when can they not? Lee Hooper Senior Lecturer in research synthesis & nutrition l.hooper@uea.ac.uk 01603 591268 Aims Systematic Reviews Discuss the scientific
More informationSupplementary materials
Supplementary materials Kedzior, K.K., Gellersen, H., Brachetti, A., Berlim, M.T., 2015. Deep transcranial magnetic stimulation (DTMS) in the treatment of major depression: an exploratory systematic review
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationBCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib
BCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib Protocol Code Tumour Group Contact Physician ULKCMLP Leukemia Dr. Donna Forrest ELIGIBILITY:
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationSynribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
More informationSystematic Reviews and Meta-analysis
Systematic Reviews and Meta-analysis Introduction to Clinical Research: A Two-week Intensive Course July 22, 2014 Sonal Singh, MD, MPH Assistant Professor Key messages Systematic reviews (SR) summarize
More informationResults. NeuRA Mindfulness and acceptance therapies August 2018
Introduction involve intentional and non-judgmental focus of one's attention on emotions, thoughts and sensations that are occurring in the present moment. The aim is to open awareness to present experiences,
More informationCochrane Breast Cancer Group
Cochrane Breast Cancer Group Version and date: V3.2, September 2013 Intervention Cochrane Protocol checklist for authors This checklist is designed to help you (the authors) complete your Cochrane Protocol.
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Nilotinib (Tasigna ) for the 1 st -line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase DSD: Horizon Scanning in Oncology Nr. 15
More informationEvidence-Based Medicine and Publication Bias Desmond Thompson Merck & Co.
Evidence-Based Medicine and Publication Bias Desmond Thompson Merck & Co. Meta-Analysis Defined A meta-analysis is: the statistical combination of two or more separate studies In other words: overview,
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationCritical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto
Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis
More informationAnimal-assisted therapy
Introduction Animal-assisted interventions use trained animals to help improve physical, mental and social functions in people with schizophrenia. It is a goal-directed intervention in which an animal
More informationSystematic Reviews and Meta-analysis in Aquatic therapy
Systematic Reviews and Meta-analysis in Aquatic therapy Prof. Daniel Daly Ben Waller PT, MSc 2nd European Congress on Evidence Based Aquatic Therapy Wednesday 15th April 2015 Systematic Review A systematic
More informationLong-term side effects, comorbidities & their impact on choice of treatment CML management and quality of life. Andreas Hochhaus
Long-term side effects, comorbidities & their impact on choice of treatment CML management and quality of life Andreas Hochhaus Frankfurt I 27.5.2017 sola dosis facit venenum Paracelsus 1493-1541 Swiss
More informationCochrane Bone, Joint & Muscle Trauma Group How To Write A Protocol
A p r i l 2 0 0 8 Cochrane Bone, Joint & Muscle Trauma Group How To Write A Protocol This booklet was originally produced by the Cochrane Renal Group to make the whole process of preparing a protocol as
More informationCochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library)
A systematic review of smoking cessation and relapse prevention interventions in parents of babies admitted to a neonatal unit (after delivery) Divya Nelson, Sarah Gentry, Caitlin Notley, Henry White,
More informationThresholds for statistical and clinical significance in systematic reviews with meta-analytic methods
Jakobsen et al. BMC Medical Research Methodology 2014, 14:120 CORRESPONDENCE Open Access Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods Janus Christian
More informationSystematic Reviews. Simon Gates 8 March 2007
Systematic Reviews Simon Gates 8 March 2007 Contents Reviewing of research Why we need reviews Traditional narrative reviews Systematic reviews Components of systematic reviews Conclusions Key reference
More informationResults. NeuRA Forensic settings April 2016
Introduction Prevalence quantifies the proportion of individuals in a population who have a disease during a specific time period. Many studies have reported a high prevalence of various health problems,
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationMeta-analysis: Advanced methods using the STATA software
Page 1 sur 5 Wednesday 20 September 2017 - Introduction to meta-analysis Introduction I. Why do a meta-analysis? II. How does a meta-analysis work? Some concepts III. Definition of an «effect size» 1.
More informationCaring for your heart during and after Chronic Myeloid Leukemia (CML) treatment
Caring for your heart during and after Chronic Myeloid Leukemia (CML) treatment For patients and families Reading this booklet can help you learn Why you were referred to the Ted Rogers Program in Cardiotoxicity
More informationMINDFULNESS-BASED INTERVENTIONS IN EPILEPSY
03 March 2016; v.1 MINDFULNESS-BASED INTERVENTIONS IN EPILEPSY AIM This review aimed to evaluate the effectiveness of mindfulness as a therapeutic intervention for people with epilepsy. METHODS Criteria
More informationQuality of meta-analyses and why they sometimes lead to different conclusions
Quality of meta-analyses and why they sometimes lead to different conclusions Jean-Pierre Pignon, MD, PhD Service de Biostatistique et d Epidémiologie, Ligue Nationale Contre le Cancer metaanalysis platform,
More informationCapture-recapture method for assessing publication bias
Received: 30.9.2009 Accepted: 19.1.2010 Original Article Capture-recapture method for assessing publication bias Jalal Poorolajal* a, Ali Akbar Haghdoost b, Mahmood Mahmoodi a, Reza Majdzadeh a, Siavosh
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Percutaneous access for endovascular aortic aneurysm repair: a systematic review and meta-analysis Shahin Hajibandeh, Shahab Hajibandeh,
More informationDistraction techniques
Introduction are a form of coping skills enhancement, taught during cognitive behavioural therapy. These techniques are used to distract and draw attention away from the auditory symptoms of schizophrenia,
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationStandards for the reporting of new Cochrane Intervention Reviews
Methodological Expectations of Cochrane Intervention Reviews (MECIR) Standards for the reporting of new Cochrane Intervention Reviews 24 September 2012 Preface The standards below summarize proposed attributes
More informationComponent of CPG development ILAE Recommendation Document Identifying topic and developing clinical. S3 research question
S1: Summary of recommendations for developing Clinical Practice Guidelines Minimum CPG development requirements (where resources are more limited) are bolded. When full resources are available, every recommendation
More informationMeta-Analyses: Considerations for Probiotics & Prebiotics Studies
Meta-Analyses: Considerations for Probiotics & Prebiotics Studies Daniel J. Tancredi, PhD Associate Professor in Residence Department of Pediatrics UC Davis School of Medicine Objectives Provide an overview
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Prophylactic cranial irradiation in patients with non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled
More information